PR1 peptide vaccine

Drug Profile

PR1 peptide vaccine

Alternative Names: NSC 698102

Latest Information Update: 23 Oct 2013

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer The Vaccine Company
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 30 Sep 2013 Discontinued - Phase-II for Myelodysplastic syndromes in USA (SC)
  • 30 Sep 2013 Discontinued - Phase-II for Chronic myeloid leukaemia in USA (SC)
  • 30 Sep 2013 Discontinued - Phase-III for Acute myeloid leukaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top